In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 85 for your search:
Drug:  imatinib mesylate
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CSTI571ADE75T, 2010-018339-16, NCT01243489
2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107ECN02, NCT01275196
3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
4.

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ISAV, 2011-002749-37, NCT01578213
5.

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107DCN03, NCT01613053
6.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE28, NCT00372476
7.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NILG-ALL 10/07, NCT00795756
8.

Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874
9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000410825, EORTC-62024, ISG-62024, FRE-FNCLCC-EORTC-62024, GEIS-EORTC-62024, EUDRACT-2004-001810-16, NCT00103168
10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 030482, NCT00219739
11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571AAT06, NCT00327262
12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: GRAALL 2005, NCT00327678
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4015-IH-CTIL, NCT00297570
14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2303, 2007-000208-34, NCT00471497
15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2405, 2009-012616-40, NCT00760877
16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2404, 2008-007054-35, NCT00802841
17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB04030, NCT00812240
18.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AMC0905, NCT01151852
20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAMN107AKR01T, NCT01400074
21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4443, 2007-006185-15, ISRCTN54923521, NCT01460693
22.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571BDE78T, NCT01462994
23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IY5511A3001, NCT01511289
24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2303E1, NCT00718263
25.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP24534-12-301, NCT01650805
1     
New Search